ImmunoGenes   Report issue

For profit Phase 2
Founded: Budapest Hungary (2007)

Organization Overview

First Clinical Trial
2015
NCT02529579
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

ImmunoGene Biotechology Co.,Ltd

Active Ingredients

Drugs in Phase 2 Trials (3)

cytotoxic t cells (1 trial)

dendritic cells (1 trial)

gemcitabine (gemzar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Pancreatic Ductal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3